Illumina Enters New Phase with Billion Cell Atlas Expansion Featuring Innovative AI Drug Developers
Illumina, Inc., a leader in genomic technology, has recently announced a significant expansion of its Billion Cell Atlas program by integrating new AI-driven drug developers. This strategic move, made public on July 16, 2026, foregrounds the participation of three new member companies, notably Formation Bio. These organizations are poised to leverage the vast genomic databases generated by the Atlas to accelerate the drug discovery process, increase efficiency, and minimize risks in bringing new therapeutics to market.
The Billion Cell Atlas, which was introduced earlier this year with founding partners such as AstraZeneca, Merck, and Eli Lilly, serves as a monumental infrastructure for understanding the complex interactions between drugs and diseases at a cellular level. Rami Mehio, Illumina's Senior Vice President and General Manager of BioInsight, emphasized the program's goal to address persistent bottlenecks in drug discovery and development. By creating foundational frameworks for training virtual models of cells, the program aims to provide insights that could resolve some fundamental challenges in biological science.
Since its launch in January 2026, the Atlas has successfully sequenced over 350 million cells to date, resulting in an immense reserve of genomic data exceeding six petabytes. This unprecedented scale allows researchers to uncover and validate novel therapeutic targets, understand drug mechanisms of action, and investigate potential new indications for existing treatments. With this wealth of data, the Atlas aims to illuminate the biological pathways that lead to diseases, thereby paving the way for innovative approaches to therapy.
Formation Bio's CEO, Benjamine Liu, shared his enthusiasm regarding the collaboration with Illumina, stating that the integration of AI and advanced technologies is essential for the rapid development of promising medicines, particularly those nearing clinical application. The approach hinges on making informed decisions about asset selection and indication based on the expansive datasets provided by the Billion Cell Atlas. Liu notes that this partnership could significantly refine their target-indication pairs by adding another dimension of cell-specific causal biology.
This cross-industry collaboration signifies a new chapter in drug discovery, emphasizing the need for a comprehensive biological understanding that goes beyond observational data. Until now, data on single cells has primarily remained superficial; however, the advent of large-scale single-cell perturbation studies opens new avenues for understanding therapeutic interactions.
Kyle Farh, Vice President of Artificial Intelligence at Illumina, highlighted the initiative's aim to redefine the trajectory of biology by facilitating the creation of foundational training datasets. By moving towards an era of data-driven insights, the program strives to uncover critical success factors for first-in-class medications, where the clinical outcomes are often ambiguous. Integrating the Atlas’s detailed perturbation data with genetic and clinical evidence can help researchers make informed choices about which drugs to advance and which patient populations are most likely to benefit.
Looking ahead, the Billion Cell Atlas is set to become the world's most comprehensive map of human disease biology. As it expands, it will deepen our understanding of how genetic variations affect individual responses to therapies, thereby revolutionizing both drug development and individual patient care. Illumina's unwavering focus remains on harnessing the power of the genome to improve global health. This initiative not only places Illumina at the forefront of technological advancements in genomics but also speaks to the company's mission of enhancing human health through innovation.
In conclusion, the expansion of the Billion Cell Atlas with new AI drug developers like Formation Bio propels the potential for developing more precise and effective medicines. This collaborative effort is anticipated to significantly impact drug approval processes, representing a leap forward in the quest for novel therapeutics tailored to individual biological contexts. By marrying genomic data with cutting-edge AI technologies, Illumina and its partners are poised to transform the landscape of biomedical research and treatment options in the years to come.
The Billion Cell Atlas, which was introduced earlier this year with founding partners such as AstraZeneca, Merck, and Eli Lilly, serves as a monumental infrastructure for understanding the complex interactions between drugs and diseases at a cellular level. Rami Mehio, Illumina's Senior Vice President and General Manager of BioInsight, emphasized the program's goal to address persistent bottlenecks in drug discovery and development. By creating foundational frameworks for training virtual models of cells, the program aims to provide insights that could resolve some fundamental challenges in biological science.
Since its launch in January 2026, the Atlas has successfully sequenced over 350 million cells to date, resulting in an immense reserve of genomic data exceeding six petabytes. This unprecedented scale allows researchers to uncover and validate novel therapeutic targets, understand drug mechanisms of action, and investigate potential new indications for existing treatments. With this wealth of data, the Atlas aims to illuminate the biological pathways that lead to diseases, thereby paving the way for innovative approaches to therapy.
Formation Bio's CEO, Benjamine Liu, shared his enthusiasm regarding the collaboration with Illumina, stating that the integration of AI and advanced technologies is essential for the rapid development of promising medicines, particularly those nearing clinical application. The approach hinges on making informed decisions about asset selection and indication based on the expansive datasets provided by the Billion Cell Atlas. Liu notes that this partnership could significantly refine their target-indication pairs by adding another dimension of cell-specific causal biology.
This cross-industry collaboration signifies a new chapter in drug discovery, emphasizing the need for a comprehensive biological understanding that goes beyond observational data. Until now, data on single cells has primarily remained superficial; however, the advent of large-scale single-cell perturbation studies opens new avenues for understanding therapeutic interactions.
Kyle Farh, Vice President of Artificial Intelligence at Illumina, highlighted the initiative's aim to redefine the trajectory of biology by facilitating the creation of foundational training datasets. By moving towards an era of data-driven insights, the program strives to uncover critical success factors for first-in-class medications, where the clinical outcomes are often ambiguous. Integrating the Atlas’s detailed perturbation data with genetic and clinical evidence can help researchers make informed choices about which drugs to advance and which patient populations are most likely to benefit.
Looking ahead, the Billion Cell Atlas is set to become the world's most comprehensive map of human disease biology. As it expands, it will deepen our understanding of how genetic variations affect individual responses to therapies, thereby revolutionizing both drug development and individual patient care. Illumina's unwavering focus remains on harnessing the power of the genome to improve global health. This initiative not only places Illumina at the forefront of technological advancements in genomics but also speaks to the company's mission of enhancing human health through innovation.
In conclusion, the expansion of the Billion Cell Atlas with new AI drug developers like Formation Bio propels the potential for developing more precise and effective medicines. This collaborative effort is anticipated to significantly impact drug approval processes, representing a leap forward in the quest for novel therapeutics tailored to individual biological contexts. By marrying genomic data with cutting-edge AI technologies, Illumina and its partners are poised to transform the landscape of biomedical research and treatment options in the years to come.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.